H.C. Wainwright raised the firm’s price target on Solid Biosciences (SLDB) to $20 from $16 and keeps a Buy rating on the shares following the Q4 report. The firm believes the company’s most important recent milestone is the release of “robust” initial clinical data for SGT-003 from the ongoing Phase 1/2 INSPIRE DUCHENNE study. Citing SGT-003’s robust initial clinical data, the firm increased the probability of launch of SGT-003 to 33% from 25%.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SLDB:
- Solid Biosciences: Promising Gene Therapy Advancements and Strategic Pipeline Expansion Justify Buy Rating
- Solid Biosciences: Positive DMD Program Developments and Strong Financial Position Justify Buy Rating
- Solid Biosciences files to sell 364,990 shares of common stock for holders
- Solid Biosciences files to sell 975,496 shares of common stock for holders
- Solid Biosciences reports Q4 EPS ($1.00), consensus (78c)